Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom

Health and Quality of Life Outcomes

Research

Arie Barlev¹  Beth Barber¹  Merel Gijsen²  Casey Quinn²  Mike Aristides² 

[1] Amgen GHE, Thousand Oaks, USA;PRMA Consulting, Fleet, UK;

关键词: Leukemia;    Lymphoblastic;    Acute;    Precursor B-cell;    Health-related quality of life;    Stated preference;    Utility value;   

DOI  :  10.1186/s12955-015-0377-3

 received in 2015-03-20, accepted in 2015-11-03,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTo date, reliable and comprehensive health-related quality of life data for patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) have not been collected in clinical trials of the disease, and no utility studies have been published. The purpose of this study was to define and validate health states experienced by adults with relapsed/refractory B-precursor ALL, and to assign utility values to these health states using time-trade off methodology.MethodsThis study was conducted in the UK in three phases. In the first phase, five health state descriptions were developed based on a recent clinical trial. The second phase validated the health state descriptions with clinicians and patients with experience of relapsed/refractory B-precursor ALL. The third phase involved prospective health state valuation using time-trade off methodology in a sample of the general public. The study was approved by the UK National Health Service Research Ethics Committee.ResultsIn total, 123 participants were recruited and included in the final analysis; all participants gave written, informed consent. Complete remission was the most preferred health state (mean utility [SEM], 0.86 [0.01]), followed by complete remission with partial hematological recovery (with minimal risk of bleeding or developing infection) (0.75 [0.02]); aplastic bone marrow (0.59 [0.02]); partial remission (0.50 [0.03]); and progressive disease (0.30 [0.04]).ConclusionsThis is the first study to report utility values for health states associated with relapsed/refractory B-precursor ALL. It was designed and conducted to align with NICE guidance on alternative methods for generating health state utility values when EQ-5D data are either unavailable or inappropriate. These utilities can be applied in future cost-effectiveness analyses of treatment for relapsed/refractory B-precursor ALL.

【 授权许可】

CC BY   
© Aristides et al. 2015